Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 74.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 38,833 shares of the company’s stock after purchasing an additional 16,625 shares during the period. Kestra Private Wealth Services LLC’s holdings in Novo Nordisk A/S were worth $4,017,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. CNB Bank purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $26,000. Pacific Center for Financial Services raised its position in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares during the period. Valued Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $28,000. Bell Investment Advisors Inc raised its position in shares of Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after buying an additional 127 shares during the period. Finally, Tyler Stone Wealth Management raised its position in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after buying an additional 146 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 1.1 %

Novo Nordisk A/S stock opened at $128.28 on Wednesday. Novo Nordisk A/S has a twelve month low of $75.56 and a twelve month high of $138.28. The stock’s fifty day simple moving average is $127.05 and its 200-day simple moving average is $112.58. The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $575.66 billion, a P/E ratio of 47.42, a P/E/G ratio of 2.12 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The firm had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on NVO. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target on the stock. UBS Group initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Finally, BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.